Incyte (MEX:INCY) Institutional Ownership: 56.85% (As of Jul. 26, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:INCY Incyte Corp MEX:INCY
84 GF Score
Price MXN2,036.00
GF Value MXN1,735.80
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Incyte Institutional Ownership?

Incyte MEX:INCY 84 Institutional Ownership is 56.85% as of Jul. 26, 2026. GuruFocus rates MEX:INCY with a GF Score™ of 84/100 and a GF Value™ of MXN1,735.80 (Modestly Overvalued). The stock has 4 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Incyte's institutional ownership is 56.85%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Incyte's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Incyte's Float Percentage Of Total Shares Outstanding is 58.06%.

Incyte Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Incyte's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Incyte Institutional Ownership Chart

Incyte Historical Data

The historical data trend for Incyte can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 56.81 57.34 57.99 57.05 56.93 57.30 57.50 57.91 57.48 56.85
MEX:INCY
84GF Score
Incyte Corp MEX:INCY
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Incyte Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 56.85% mean?
Incyte (MEX:INCY) has a Institutional Ownership of 56.85% as of Jul. 26, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Incyte and its competitors.
Is Incyte's Institutional Ownership too high?
Incyte's current Institutional Ownership is 56.85%. Overall, Incyte has a GF Score™ of 84/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Incyte's Institutional Ownership compare to INSM and BNTX?
Incyte's Institutional Ownership of 56.85% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Incyte and its competitors. Incyte's current Institutional Ownership is 56.85%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Incyte stock overvalued right now?
Based on GuruFocus' analysis, Incyte (MEX:INCY) is currently considered Modestly Overvalued. The stock's GF Value™ is MXN1,735.80, compared to a current price of MXN2,036.00 — trading 17.3% above its estimated fair value. The current Institutional Ownership is 56.85%. Incyte's overall GF Score™ is 84/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Incyte (MEX:INCY), the current Institutional Ownership is 56.85% as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Incyte (MEX:INCY) Overvalued in 2026?

Based on GuruFocus' analysis, Incyte stock appears to be overvalued. The current stock price of MXN2,036.00 is trading 17.3% above its estimated GF Value™ of MXN1,735.80. GuruFocus considers Incyte to be Modestly Overvalued.

Key valuation signals for MEX:INCY:

  • Institutional Ownership: 56.85%
  • GF Value™: MXN1,735.80 vs. price of MXN2,036.00 (17.3% above fair value)
  • GF Score™: 84/100 with 4 warning signs

No single metric tells the full story. See the MEX:INCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Incyte Business Description

Address 1801 Augustine Cut-Off, Wilmington, DE, USA, 19803
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.
84GF Score

Get the complete analysis for MEX:INCY

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN2,036.00
Price
MXN1,735.80
GF Value